Acute bacterial skin and skin-structure infections
Recce Pharmaceuticals develops therapies targeting resistant bacteria to treat acute bacterial skin and skin structure infections (ABSSSI).
recce.com.auCrawled Nov 11, 2026
Recce Pharmaceuticals develops therapies targeting resistant bacteria to treat acute bacterial skin and skin structure infections (ABSSSI).
Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) provides information on diabetic foot infections (DFI), the leading cause of nontraumatic foot amputations in diabetics
Recce focuses on developing broad-spectrum antibiotics to treat resistant and hard-to-treat infections.
Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) offers RECCE 327 for bacterial and RECCE 529 for viral infections, with a focus on 'difficult to treat' cases.
Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) addresses Sepsis, a life-threatening infection response, highlighting the urgent need for effective treatments.
UTIs cause 30% of Sepsis (Urosepsis). R327's potential addresses this unmet medical need, offering therapy across the infectious disease journey.
Recce Pharmaceuticals includes a diverse Board of Directors and Management team who are experts in clinical research and business development.
Recce Pharmaceuticals is pioneering synthetic anti-infectives, with its lead compound, RECCE 327, targeting a broad range of drug-resistant bacteria.
Recce Pharmaceuticals (ASX: RCE) and its Board of Directors prioritise effective, transparent, and ethical governance for efficient organisational management.
Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) holds 4 patent families with 30+ patents, actively expanding and safeguarding its intellectual property for commercial and clinical advantages.
Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) Sydney facility meets pharmaceutical standards and produces RECCE 327 with 99.9% yield at 500 doses/hour, demonstrating quality and volume for clinical trials.
Recce Pharmaceuticals (ASX: RCE) pioneers a New Class of Synthetic Anti-infectives to combat antibiotic-resistant superbugs.
Recce demonstrates promising results for its topical gel in treating diabetic foot infections, based on data reviewed before Phase III trials. The gel targets bacterial infections common in diabetic patients, offering a potential localized treatment option.
Recce is developing a commercial strategy for its novel antibacterial platform. The company aims to address growing antimicrobial resistance by introducing new treatment options. Early-stage efforts focus on validating efficacy and regulatory pathways for potential clinical applications.
Recce Pharmaceuticals secures approval to directly compare its experimental compound **R327G** with conventional antibiotics in clinical trials. The move positions R327G as a potential alternative in treating bacterial infections, leveraging Recce’s proprietary platform for antimicrobial discovery.
Recce moves its anti-infective gel into Phase III clinical trials targeting diabetic foot infections. The trial takes place in Australia, focusing on treating a high-risk complication for diabetic patients. The gel is designed to combat bacterial infections in wounds associated with diabetes.
Recce secures a 10-year licensing agreement covering the Middle East and North Africa (MENA) region. The deal expands the company’s operational footprint in a key market with significant growth potential.
Recce completes a regulatory inspection for its Phase III clinical trial targeting diabetic foot infections in Indonesia. The trial, now cleared, advances toward further testing in the country. The company focuses on developing treatments for diabetic foot infections, a significant medical challenge.